In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients

John Christenson, E. Kent Korgenski, Judy A. Daly

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We studied 67 Pseudomonas aeruginosa isolates from cystic fibrosis patients, and compared their in vitro susceptibility to two carbapenems (meropenem and imipenem) and two cephalosporins (cefepime and ceftazidime). The carbapenems were more effective in vitro than the cephalosporins: 92.5% of isolates were susceptible to the former and 77.6% to the latter. Essentially no difference was found between meropenem and imipenem. More discrepancies were seen between cefepime and ceftazidime: four of 67 isolates (6.0%) were more susceptible to cefepime than to ceftazidime, while eight (11.9%) were more susceptible to ceftazidime than to cefepime.

Original languageEnglish (US)
Pages (from-to)899-901
Number of pages3
JournalJournal of Antimicrobial Chemotherapy
Volume45
Issue number6
StatePublished - 2000
Externally publishedYes

Fingerprint

meropenem
Ceftazidime
Imipenem
Cystic Fibrosis
Pseudomonas aeruginosa
Carbapenems
Cephalosporins
cefepime
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. / Christenson, John; Korgenski, E. Kent; Daly, Judy A.

In: Journal of Antimicrobial Chemotherapy, Vol. 45, No. 6, 2000, p. 899-901.

Research output: Contribution to journalArticle

@article{440fdbc8af5a404ebd05ddb23685e039,
title = "In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients",
abstract = "We studied 67 Pseudomonas aeruginosa isolates from cystic fibrosis patients, and compared their in vitro susceptibility to two carbapenems (meropenem and imipenem) and two cephalosporins (cefepime and ceftazidime). The carbapenems were more effective in vitro than the cephalosporins: 92.5{\%} of isolates were susceptible to the former and 77.6{\%} to the latter. Essentially no difference was found between meropenem and imipenem. More discrepancies were seen between cefepime and ceftazidime: four of 67 isolates (6.0{\%}) were more susceptible to cefepime than to ceftazidime, while eight (11.9{\%}) were more susceptible to ceftazidime than to cefepime.",
author = "John Christenson and Korgenski, {E. Kent} and Daly, {Judy A.}",
year = "2000",
language = "English (US)",
volume = "45",
pages = "899--901",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients

AU - Christenson, John

AU - Korgenski, E. Kent

AU - Daly, Judy A.

PY - 2000

Y1 - 2000

N2 - We studied 67 Pseudomonas aeruginosa isolates from cystic fibrosis patients, and compared their in vitro susceptibility to two carbapenems (meropenem and imipenem) and two cephalosporins (cefepime and ceftazidime). The carbapenems were more effective in vitro than the cephalosporins: 92.5% of isolates were susceptible to the former and 77.6% to the latter. Essentially no difference was found between meropenem and imipenem. More discrepancies were seen between cefepime and ceftazidime: four of 67 isolates (6.0%) were more susceptible to cefepime than to ceftazidime, while eight (11.9%) were more susceptible to ceftazidime than to cefepime.

AB - We studied 67 Pseudomonas aeruginosa isolates from cystic fibrosis patients, and compared their in vitro susceptibility to two carbapenems (meropenem and imipenem) and two cephalosporins (cefepime and ceftazidime). The carbapenems were more effective in vitro than the cephalosporins: 92.5% of isolates were susceptible to the former and 77.6% to the latter. Essentially no difference was found between meropenem and imipenem. More discrepancies were seen between cefepime and ceftazidime: four of 67 isolates (6.0%) were more susceptible to cefepime than to ceftazidime, while eight (11.9%) were more susceptible to ceftazidime than to cefepime.

UR - http://www.scopus.com/inward/record.url?scp=0034091464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034091464&partnerID=8YFLogxK

M3 - Article

C2 - 10837448

AN - SCOPUS:0034091464

VL - 45

SP - 899

EP - 901

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 6

ER -